Alexander Kornelyuk

Alexander Kornelyuk

Auto-generated profile, based on publicly available information

Alexander Kornelyuk

Інститут молекулярної біології і генетики НАН України, Україна, 03143, м Київ, вул. Акад. Заболотного, 150

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2004 in Proteins: Structure, Function, and Bioinformatics
Verified
Journal Article
Open access
PDF file
DKDmytro Kovalskyy
Dmytro Kovalskyy
VDVolodymyr Dubyna
Volodymyr Dubyna
AMAlan E. Mark
Alan E. Mark
AKAlexander Kornelyuk
Alexander Kornelyuk
HIV-1 protease is most active under weakly acidic conditions (pH 3.5–6.5), when the catalytic Asp25 and Asp25′ residues share 1 proton. At neutral pH, this proton is lost and the stability of the structure is reduced. Here we present an investigation of the effect of pH on the dynamics of HIV-1 protease using MD simulation techniques. MD simulations of the solvated HIV-1 protease with the Asp25/25′ residues monoprotonated and deprotonated have been performed. In addition we investigated the effect of the inclusion of Na+ and Cl− ions to mimic physiological salt conditions. The simulations of the monoprotonated form and deprotonated form including Na+ show very similar behavior. In both cases the protein remained stable in the compact, “self-blocked” conformation in which the active site is blocked by the tips of the flaps. In the deprotonated system a Na+ ion binds tightly to the catalytic dyad shielding the repulsion between the COO− groups. Ab initio calculations also suggest the geometry of the active site with the Na+ bound closely resembles that of the monoprotonated case. In the simulations of the deprotonated form (without Na+ ions), a water molecule bound between the Asp25 Asp25′ side-chains. This disrupted the dimerization interface and eventually led to a fully open conformation. Proteins 2005.

20 November 1991 in Biopolymers and Cell
Verified
Journal Article
Open access
IKI. V. Klimenko
I. V. Klimenko
TGT. O. Guscha
T. O. Guscha
AKA. I. Kornelyuk
A. I. Kornelyuk

19 June 2025 in Visnik Nacional noi academii nauk Ukrai ni
Verified
Journal Article
Open access
PDF file
ОКОлександр Іванович Корнелюк
Олександр Іванович Корнелюк
Як цитувати: Корнелюк О.І. Штучний інтелект і моделювання просторової структури протеїнів (стенограма виступу на сесії Загальних зборів НАН України 30 квітня 2025 р.). Вісник НАН України. 2025. № 6. С. 72—74. https://doi.org/10.15407/visn2025.06.072

1 September 2025 in Faktori eksperimental'noi evolucii organizmiv
Verified
Journal Article
Open access
PDF file
ISI. M. Shuba
I. M. Shuba
VLV. V. Lylo
V. V. Lylo
IKI. S. Karpova
I. S. Karpova
OGO. Y. Glavatskyi
O. Y. Glavatskyi
OKO. I. Kornelyuk
O. I. Kornelyuk
Aim. Confirmation of the previously established (by MTT assay) cytotoxic potential of the EMAP II polypeptide against primary glioblastoma cell culture using an independent method of trypan blue exclusion test, which is widely used for selective cell staining. Methods. Primary cell culture obtained from malignant glioma tissue fragments after surgery was treated with EMAP II at various concentrations. The trypan blue dye exclusion test was used to determine the number of viable cells present in the cell suspension. In this case, living cells, which have intact cell membranes, remain transparent due to the exclusion of the dye, while dead cells absorb the dye and turn blue. Results. A dose-dependent cytotoxic effect of EMAP II was recorded, which was manifested in the range of high drug concentrations 10 μM, 2 μM, 640 pM. Conclusions. The trypan blue exclusion test, due to its simplicity and availability, can be used for preliminary screening studies of the effect of EMAP II on malignant glioma cells, but it is significantly inferior to the MTT-test in sensitivity and informativeness.

1 September 2023 in Faktori eksperimental'noi evolucii organizmiv
Verified
Journal Article
Open access
PDF file
ISI. M. Shuba
I. M. Shuba
VLV. V. Lylo
V. V. Lylo
IKI. S. Karpova
I. S. Karpova
OGO. Y. Glavatskyi
O. Y. Glavatskyi
OKO. I. Kornelyuk
O. I. Kornelyuk
Aim. To evaluate with the use of the MTT test how the formation of a nanocomposite complex of the cytokine EMAP II with dextran-70 affects the cytotoxic effect of the free protein in glioma cell cultures of different origins: a standart culture U251MG cells and a primary culture of cells obtained from tumor fragments. Methods. The recombinant polypeptide EMAP II was obtained using gene engineering biotechnology. The study was conducted on the standard human glioma cell line U251MG and on primary cell cultures obtained from tumor fragments after surgical removal. Cell viability was determined using the MTT test. The cells were cultivated for a day with t the different concentrations from 1.0 pM to 10 μM of EMAP II and the EMAP II + dextran-70 complex im serum-free standard DMEM growth medium. Results. In our previous works, it has been shown that EMAP II exhibited dose-dependent cytotoxic properties in the concentration range of 1.0 pM – 10 μM on U251MG glioma cells and in primary cell cultures. The dose-effect curve in all cases has a complex pattern. Dextran-70 does not fundamentally affect the cytotoxic effect of EMAP II, but depending on the dose and type of cells, it shows the ability to slightly weaken/enhance the effect of the free protein. An increased sensitivity of the primary culture of glioma cells to the cytotoxic effect of the EMAP II + dextran-70 complex was revealed. Conclusions. Dextran-70 does not fundamentally affect the cytotoxic effect of EMAP II, but depending on the dose and type of cells, it shows the ability to slightly weaken/enhance the effect of the latter.